Clay Siegall and Targeted Therapy Drugs

If you haven’t heard of Dr. Clay Siegall, he is the Founder and CEO of Seattle Genetics, a biotechnology company predicated on the development of targeted therapy drugs. In layman’s terms, these are drugs aimed at delivering a concentration of medication to a specific part of the body, localized cancers being a primary example. Since being founded in 1998, Dr. Siegall and his team at Seattle Genetics have worked diligently towards creating pharmacotherapies aimed at improving mortality rates, in those who have been diagnosed with serious diseases. In fact, in November 2017, Seattle Genetics received FDA approval for one of their antibody drug conjugates, Adcetris. The drug is reportedly used to treat patients diagnosed with Hodgkin lymphoma and systemic anaplastic large cell lymphoma.

According to his Linkedin bio, Dr. Siegall attended George Washinton University, where he earned a Ph.D. in Genetics. Shortly thereafter, he earned a B.S. in Zoology from the University of Maryland. In an interview with inspirey.com, Dr. Siegall delineates the impetus for his interest in medicine, in what could only be described as veritable candor; he describes having to witness a family member undergo a cancer treatment regimen that nearly resulted in their death. It was at this point when the idea of pursuing a career in medicine began to flourish.

Prior to his role as Founder and CEO of Seattle Genetics, Dr. Clay Siegall worked with Bristol-Myers Squibb, where he served as the company’s Senior Research Investigator from 1991 to 1995. In 1995, he became the company’s Principal Scientist, maintaining that role until 1997, before establishing Seattle Genetics in 1998. In addition to his work in cancer research and therapeutic drug development, Dr. Siegall has also served as the Director for Washington Biotechnology and Biomedical Association, as well as non-executive Director for Mirna Therapeutics, Inc.

Collectively, Dr. Clay Siegall has a well over 20-years of industry experience and has written upwards of 67 scientific papers, easily making him one of the foremost experts in the world of cancer research. Dr. Seigall currently sits on the editorial board for three scientific journals and has been the recipient of several awards, including the Pacific Northwest Ernst and Young Entrepreneur of the year, as well as University of Maryland’s Alumnus of the year.

0 thoughts on “Clay Siegall and Targeted Therapy Drugs”

Leave a Reply

Your email address will not be published. Required fields are marked *